Insider · CIK 0001370820

Alder Matthias

Reports to the SEC for 3 companies · BETHESDA, MD

sec.gov

Transactions

Companies

Filings

CIK

0001370820

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2024-03-26	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−18.8K sh	—	—	56,250
2024-03-26	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−637 sh	—	—	6,376
2024-03-26	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−825 sh	—	—	8,250
2024-03-26	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+18.8K sh	—	—	25,763
2024-03-26	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+825 sh	—	—	26,588
2024-03-26	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+637 sh	—	—	27,225
2024-03-26	GANXGain Therapeutics, Inc.F Tax Payment	Director, Chief Executive Officer	FTax Payment	−6,085 sh	$4.06	−$24.7K	21,140
2024-03-21	GANXGain Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+370K sh	—	—	370,000
2023-12-21	GANXGain Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−206 sh	$2.46	−$506.76	5,286
2023-12-20	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+637 sh	—	—	5,492
2023-12-20	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−637 sh	—	—	7,013
2023-12-07	GANXGain Therapeutics, Inc.S Sale	Director, Chief Executive Officer	SSale	−1,820 sh	$2.50	−$4,550	4,855
2023-10-01	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−825 sh	—	—	9,075
2023-10-01	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+825 sh	—	—	6,675
2023-09-20	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+2,550 sh	—	—	5,850
2023-09-20	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−2,550 sh	—	—	7,650
2023-07-01	GANXGain Therapeutics, Inc.M Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	+3,300 sh	—	—	3,300
2023-07-01	GANXGain Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, Chief Executive Officer	MExercise/Conversion	−3,300 sh	—	—	9,900
2023-03-23	GANXGain Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+75K sh	—	—	75,000
2023-03-23	GANXGain Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+150K sh	—	—	150,000
2022-09-20	GANXGain Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+60.9K sh	—	—	60,900
2022-09-20	GANXGain Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+10.2K sh	—	—	10,200
2022-07-15	GANXGain Therapeutics, Inc. · Employee Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+79.2K sh	—	—	79,200
2022-07-15	GANXGain Therapeutics, Inc. · Restricted Stock UnitsA Award	Director, Chief Executive Officer	AAward	+13.2K sh	—	—	13,200
2021-12-23	GANXGain Therapeutics, Inc. · Non Qualified Stock Option (right to buy)A Award	Director, Chief Executive Officer	AAward	+200K sh	$5.86	+$1.17M	200,000
2017-06-30	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+673 sh	$8.93	+$6,009.89	4,763
2017-03-31	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+641 sh	$9.35	+$5,993.35	4,224
2017-03-06	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)A Award	EVP, Gen. Council & Sec.	AAward	+63K sh	—	—	325,500
2017-03-06	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+33K sh	—	—	33,000
2016-12-31	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+134 sh	$10.46	+$1,401.64	3,583
2016-11-28	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	−25K sh	—	—	262,500
2016-11-28	Sucampo Pharmaceuticals, Inc.S Sale	EVP, Gen. Council & Sec.	SSale	−25K sh	$16.73	−$418K	3,449
2016-11-28	Sucampo Pharmaceuticals, Inc.M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	+25K sh	$8.33	+$208K	28,424
2016-11-25	Sucampo Pharmaceuticals, Inc.M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	+99K sh	$8.33	+$825K	102,474
2016-11-25	Sucampo Pharmaceuticals, Inc.S Sale	EVP, Gen. Council & Sec.	SSale	−99K sh	$15.88	−$1.57M	3,449
2016-11-25	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	−99K sh	—	—	287,475
2016-11-23	Sucampo Pharmaceuticals, Inc.S Sale	EVP, Gen. Council & Sec.	SSale	−26K sh	$15.77	−$410K	3,449
2016-11-23	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	−26K sh	—	—	386,500
2016-11-23	Sucampo Pharmaceuticals, Inc.M Exercise/Conversion	EVP, Gen. Council & Sec.	MExercise/Conversion	+26K sh	$8.33	+$217K	29,449
2016-09-30	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+639 sh	$9.38	+$5,993.82	3,449
2016-06-30	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+752 sh	$9.32	+$7,008.64	2,810
2016-03-31	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+645 sh	$9.29	+$5,992.05	2,058
2016-03-02	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)A Award	EVP, Gen. Council & Sec.	AAward	+62.5K sh	—	—	412,500
2015-12-31	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+477 sh	$14.70	+$7,011.9	1,413
2015-09-30	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+413 sh	$14.52	+$5,996.76	936
2015-06-30	Sucampo Pharmaceuticals, Inc.A Award	EVP, Gen. Council & Sec.	AAward	+523 sh	$13.37	+$6,992.51	523
2015-03-04	Sucampo Pharmaceuticals, Inc.Employee Stock Option (right to buy)A Award	EVP, Gen. Council & Sec.	AAward	+50K sh	—	—	350,000
2012-03-07	MICROMET, INC.Stock Option (right to buy)D Disposition to Issuer	SVP, GC and Secretary	DDisposition to Issuer	−1,429 sh	$9.25	−$13.2K	0
2012-03-07	MICROMET, INC.Stock Option (right to buy)D Disposition to Issuer	SVP, GC and Secretary	DDisposition to Issuer	−59.4K sh	$7.84	−$466K	0
2012-03-07	MICROMET, INC.Stock Option (right to buy)D Disposition to Issuer	SVP, GC and Secretary	DDisposition to Issuer	−113K sh	$5.17	−$582K	0

Recent filings

Accepted (ET)
Mar 284
Alder Matthias0001493152-24-011836
SEC(opens sec.gov)
Mar 254
Alder Matthias0001493152-24-011215
SEC(opens sec.gov)
Dec 224
Alder Matthias0001209191-23-059558
SEC(opens sec.gov)
Dec 144
Alder Matthias0001104659-23-126020
SEC(opens sec.gov)
Oct 34
Alder Matthias0001209191-23-051502
SEC(opens sec.gov)
Sep 224
Alder Matthias0001209191-23-050379
SEC(opens sec.gov)
Jul 54
Alder Matthias0001209191-23-041027
SEC(opens sec.gov)
Mar 274
Alder Matthias0001209191-23-021257
SEC(opens sec.gov)

Companies

Address

C/O MICROMET, INC. 6707 DEMOCRACY BLVD., STE. 505

BETHESDA, MD, 28017